Top News

First patient enrolled in phase III study of abicipar - Molecular Partners receives USD 15 million milestone payment

SBA Member News, 07.07.2015

• Phase III clinical trial of abicipar started in line with communicated timelines
• Milestone payment of USD 15 million triggered to Molecular Partners
• First product from promising DARPin platform in phase III development


Ein Star kommt nach Solothurn

Schweiz am Sonntag , 06.07.2015

Next Event


Community Login

Bachem Holding AG